ENSC

Investor Moves

Name	Value	Action	Change	Price	Current Price
Jim SimonsRenaissance Technologies $-36.9K ExitQ4 2025 $37k -- --
Ken GriffinCitadel Advisors $-34.4K ExitQ4 2025 $34k -- --

News

accessnewswire.comEnsysce Biosciences Reports First Quarter 2026 Financial Resultsaccessnewswire.comMay 15

accessnewswire.comEnsysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technologyaccessnewswire.comMay 12

accessnewswire.comEnsysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdamaccessnewswire.comMay 8

accessnewswire.comEnsysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Studyaccessnewswire.comApr 16

accessnewswire.comEnsysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programsaccessnewswire.comApr 7

Trade ENSC

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.

CEO: D. Lynn Kirkpatrick
IPO Date: Mar 14, 2018

Market Data

Open: $0.2672
High: $0.2899
Low: $0.2625
Volume: 1.4M
Avg Volume: 2.1M
52W High: $2.75
52W Low: $0.23

Valuation

Market Cap: $2.5M
Enterprise Value: $2.0M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-7806B
Revenue: $5.1M
Net Income: $-10M
Cash: $4.3M
Debt: $307B

Events

EarningsAug 12

EPS est. -0.5